I n d e x e d i n P u b M e d , W e b o f S c i e n c e a n d S c o p u s Bakhman Guliev et al.; The use of the three-dimensional printed segmented collapsible model of the pelvicalyceal system to improve residents' learning curve.
Aim: To determine the diseases that presented to the urology department during the COVID-19 pandemic and for hospital-based comparison with the diseases that presented in the same period of the previous year.
Material and Method: In this retrospective follow-up study, patients who were admitted to the tertiary university hospital and secondary state hospital urology departments between April-July 2019 and April-July 2020 were included in the study. We searched the health administrative data using the International Classification of Diseases-10 codes. The number and variety of patients who were admitted to the urology departments in the same months of 2019 and 2020 were compared.
Results: In both hospitals, the total number of admissions decreased during the pandemic in 2020 compared to the pre-pandemic year. Also, elective admissions decreased in 2020 compared to the pre-pandemic year (p
for secondary procedures (defined as removal, revision or replacement of any or all components). RESULTS: 2335 patients underwent primary AUS implantation between 2003-2014. Median age was 69 years, 67.9% were Caucasian, and 4.5% had a neurogenic bladder. The rates of primary AUS decreased over the course of the study period (p[0.011, Figure 1).After primary AUS implantation, 27.5% underwent secondary procedures for complications relating to urethral atrophy, infection or mechanical issues. 7.1% of patients had an infectious complication over the course of the study period.On multivariable modeling, the following factors predicted the need for a secondary procedure in patients undergoing primary AUS implantation: neurogenic bladder status (OR[1.94, p[0.009) and immunosuppression status (OR[2.19, p[0.006). Patients undergoing primary AUS implantation at a high-volume facility (top 10th percentile) had a lower risk of requiring secondary procedures (OR[0.71, p[0.021). Surgeon volume had no effect on the need for secondary procedures after controlling for facility volume. We controlled for age, race, prior radiation, immunosuppressed status, neurogenic bladder status, socioeconomic status, insurance status, facility and surgeon volume.CONCLUSIONS: There has been a gradual decrease in the use of artificial urinary sphincters in New York State between 2003-2014. Being immunosuppressed or neurogenic bladder status increases the risk of requiring secondary procedures. Higher facility volume, not surgeon volume, predicts for lower risk of requiring secondary procedures after AUS placement. The population level risk of infectious complications is higher than those reported from single surgeon series.
Introduction:To evaluate the clinical efficacy and safety of botulinum neurotoxin A injection in geriatric patients with an overactive bladder.Materials and Method: Data of 34 patients aged >65 years who received botulinum neurotoxin A injections (100 U) for overactive bladder at two different urology clinics from 2012 to 2018were retrospectively evaluated. Number of incontinence episodes, urinary frequency, nocturia occurrence, daily pad usage, maximum flow rate, post-void residual urine volume, treatment benefit scale and quality of life scores were evaluated for all patients at pretreatment and then at 3 and 6 months post treatment.Results: Comparison of the pre-treatment and the 3-and 6-month post-treatment data revealedno significant changes in maximum flow rate values (p=0.504 and 0.458, respectively); however, a statistically significant decrease was recorded in the urinary frequency, nocturia occurrence, daily pad usage and number of incontinence episodes (p=0.0001). The post-void residual urine volume significantly increased at 3 and 6 months post treatment (p=0.0001). Significant improvements were detected in the quality of life score at 3-months post treatment (p=0.0001).Conclusion: Botulinum neurotoxin A injection is an efficacious and safe option for treating geriatric patients and improving their symptoms of overactive bladder and quality of life.
ABSTRACT
Giriş: Aşırı aktif mesanesi olan geriatrik hastalarda botulinum neurotoxin A enjeksiyonunun klinik etkinliğini ve güvenilirliğini değerlendirmek.Gereç ve Yöntem: 2012-2018 yılları arasında iki farklı üroloji kliniğinde aşırı aktif mesane nedeni ile botulinum nörotoksin A enjeksiyonu (100 Ü) yapılan 65 yaş ve üstündeki 34 hastanın verileri geriye dönük olarak değerlendirildi. Tedavi öncesi ve tedavi sonrası 3. ve 6. Aydaki inkontinans ataklarının sayısı, idrar sıklığı, nokturia oluşumu, günlük ped kullanımı, maksimum akış hızı, sonrasındaki rezidüel idrar hacmi, tedavi yarar ölçeği ve yaşam kalitesi skorları değerlendirildi.Bulgular: Tedavi öncesi ve tedavi sonrası 3 ve 6. aydaki verilerin karşılaştırılması, maksimum idrar akış hızı değerinde anlamlı bir değişiklik olmadığını ortaya koyarken (sırasıyla, p=0.504 ve 0.458); idrar sıklığı, nokturia oluşumu, günlük ped kullanımı ve idrar kaçırma ataklarının sayısında ise istatistiksel olarak anlamlı bir azalma kaydedildi (p=0.0001). Rezidüel idrar hacmi, tedaviden sonraki 3.ve 6 ayda önemli ölçüde artmıştır (p=0.0001). Tedavi sonrası 3. Aydaki yaşam kalitesi skorunda ise anlamlı iyileşmeler tespit edildi (p=0.0001).Sonuç: Botulinum neurotoxin A enjeksiyonu, aşırı aktif mesaneli geriatrik hastaların tedavisinde, semptomların ve yaşam kalitesinin düzeltilmesinde etkili ve güvenli bir seçenektir.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.